It is stated that ASALVO will be the most important product (in terms of sales and reputation) of all the subsidiary companies of Symborg and will strengthen and optimize the commercial network, increasing also the interest of distributors on the company products.
Additionally, it will provide resistance to the company in the markets, since with ASALVO, Symborg will be more resilient to variations in regulation, policies or competence products that could affect to its traditional activity (biostimulants).
On the other hand, the registration processes are the limiting factor for the market uptake of Asalvo, whose former products were mainly bio-stimulants, which didn’t need this long and expensive registration process. Moreover, this process is more complicated in Europe than in USA or other countries, and this also makes a difference regarding the market uptake strategy. This is due to the need of developing a double stage process in Europe, where it is necessary to register both the active substance and the commercial product, while in the USA it is necessary only to develop one of these processes and, in addition to this it is normally a faster process.
Finally, the rapid growth of Symborg needs the reinvestment of all the benefits the company achieves. This way, it is difficult for the company to afford the long investment needed for developing the registration processes of ASALVO, taking into account that the product couldn’t be on the market before 24 months (USA, Mexico, Chile, Peru) or 48 months (Europe), and this would affect seriously the current market uptake process of other products from Symborg. To solve this, additional resources are needed.
